Saturn V Capital Management
Latest statistics and disclosures from Saturn V Capital Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are ARGX, IRON, CRNX, PCVX, ASND, and represent 39.11% of Saturn V Capital Management's stock portfolio.
- Added to shares of these 10 stocks: CRGX (+$14M), CELC (+$13M), IRON (+$11M), INZY (+$5.1M), BMRN, NMRA, ELVN, PCVX, LBPH, RAPP.
- Started 8 new stock positions in CRGX, LBPH, RAPP, CELC, NMRA, INZY, ELVN, CTNM.
- Reduced shares in these 10 stocks: MRUS (-$13M), ANAB (-$8.4M), CRNX (-$8.1M), APLS, GERN, KALV, CABA, FOLD, MORF, ARGX.
- Sold out of its positions in APLS, CABA, GERN.
- Saturn V Capital Management was a net buyer of stock by $20M.
- Saturn V Capital Management has $265M in assets under management (AUM), dropping by 6.10%.
- Central Index Key (CIK): 0001964437
Tip: Access up to 7 years of quarterly data
Positions held by Saturn V Capital Management consolidated in one spreadsheet with up to 7 years of data
Download as csv Download as ExcelPortfolio Holdings for Saturn V Capital Management
Saturn V Capital Management holds 26 positions in its portfolio as reported in the June 2024 quarterly 13F filing
Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
---|---|---|---|---|---|---|
Argenx Se Sponsored Adr (ARGX) | 10.4 | $28M | -2% | 64k | 430.04 |
|
Disc Medicine (IRON) | 8.6 | $23M | +97% | 503k | 45.07 |
|
Crinetics Pharmaceuticals In (CRNX) | 8.1 | $22M | -27% | 480k | 44.79 |
|
Vaxcyte (PCVX) | 6.2 | $16M | +16% | 216k | 75.51 |
|
Ascendis Pharma A/s Sponsored Adr (ASND) | 5.8 | $15M | +9% | 113k | 136.38 |
|
Cytokinetics Com New (CYTK) | 5.6 | $15M | +3% | 272k | 54.18 |
|
BioMarin Pharmaceutical (BMRN) | 5.6 | $15M | +49% | 179k | 82.33 |
|
Cogent Biosciences (COGT) | 5.3 | $14M | +4% | 1.7M | 8.43 |
|
Cargo Therapeutics (CRGX) | 5.3 | $14M | NEW | 857k | 16.42 |
|
Kalvista Pharmaceuticals (KALV) | 5.0 | $13M | -21% | 1.1M | 11.78 |
|
Celcuity (CELC) | 4.7 | $13M | NEW | 761k | 16.38 |
|
Merus N V (MRUS) | 3.7 | $9.7M | -56% | 165k | 59.17 |
|
Syndax Pharmaceuticals (SNDX) | 3.3 | $8.6M | +5% | 420k | 20.53 |
|
Abivax Sa Sponsored Ads (ABVX) | 3.1 | $8.3M | 628k | 13.22 |
|
|
Ironwood Pharmaceuticals Com Cl A (IRWD) | 2.7 | $7.3M | +17% | 1.1M | 6.52 |
|
Amicus Therapeutics (FOLD) | 2.7 | $7.1M | -20% | 714k | 9.92 |
|
Anaptysbio Inc Common (ANAB) | 2.4 | $6.3M | -57% | 250k | 25.06 |
|
Phathom Pharmaceuticals (PHAT) | 2.3 | $6.1M | +18% | 593k | 10.30 |
|
Iteos Therapeutics (ITOS) | 2.1 | $5.5M | -5% | 367k | 14.84 |
|
Inozyme Pharma (INZY) | 1.9 | $5.1M | NEW | 1.1M | 4.46 |
|
Neumora Therapeutics (NMRA) | 1.4 | $3.8M | NEW | 390k | 9.83 |
|
Enliven Therapeutics (ELVN) | 1.3 | $3.6M | NEW | 152k | 23.37 |
|
Longboard Pharmaceuticals In (LBPH) | 0.7 | $1.9M | NEW | 71k | 27.03 |
|
Rapport Therapeutics (RAPP) | 0.6 | $1.6M | NEW | 70k | 23.26 |
|
Morphic Hldg (MORF) | 0.6 | $1.6M | -44% | 48k | 34.07 |
|
Contineum Therapeutics Cl A (CTNM) | 0.5 | $1.3M | NEW | 73k | 17.61 |
|
Past Filings by Saturn V Capital Management
SEC 13F filings are viewable for Saturn V Capital Management going back to 2022
- Saturn V Capital Management 2024 Q2 filed Aug. 14, 2024
- Saturn V Capital Management 2024 Q1 filed May 15, 2024
- Saturn V Capital Management 2023 Q3 filed Nov. 14, 2023
- Saturn V Capital Management 2023 Q2 filed Aug. 14, 2023
- Saturn V Capital Management 2023 Q1 filed May 15, 2023
- Saturn V Capital Management 2022 Q4 filed Feb. 9, 2023